Skip to main content
. 2011 Nov 22;6(11):e27547. doi: 10.1371/journal.pone.0027547

Figure 2. Tetrac inhibits thyroid hormone-induced PCNA accumulation and ERK1/2 activation in different lung carcinoma cells.

Figure 2

A. non-small cell NCI-H522 and B. small cell NCI-H510A lung carcinoma cells were treated with tetrac (10−7 M) for 30 min prior to addition of T3 (10−7 M) or T4 (10−7 M). Cells were harvested either 30 min (ERK1/2) or 24 h (PCNA) after the onset of treatment. Tetrac, alone, did not induce either ERK1/2 activation or PCNA expression; however, tetrac did block the effects of both T4 and T3 in these two cell lines by inhibition of thyroid hormone binding to the cell surface integrin receptor. * p<0.05, **p<0.01 compared with control; + p<0.05, ++p<0.01 comparing hormone effects with and without tetrac.